Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
ONE-YEAR RESULTS OF THE CONFIRMATORY CLINICAL TRIAL OF LUX-VALVE RELEASED AT THE PCR LONDON VALVES 2023

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that the one-year results of the confirmatory clinical trial of the LuX-Valve transcatheter tricuspid valve replacement system ("**LuX-Valve**") were recently officially released at the PCR London Valves 2023 by the proponent of the tricuspid risk assessment system TRI-SCORE, Professor Julien Dreyfus from Centre Hospitalier de Saint-Denis (法國巴黎聖丹尼斯醫院) in Paris, France.

The LuX-Valve confirmatory clinical trial is a prospective, multicenter and single-arm study. The confirmatory clinical study of the LuX-Valve enrolled a total of 126 patients with severe tricuspid regurgitation ("**TR**") and is designed to evaluate the safety and efficacy of LuX-Valve in patients with severe TR. The primary endpoint of the clinical trial was cumulative all-cause mortality at one year after surgery.

The one-year efficacy results showed:

The LuX-Valve significantly reduced TR, improved patients' cardiac functions and enhanced their quality of life. The ultrasonographic data showed that 99.1% of the patients had an improved TR grade, 94.4% of the patients had their TR grade reduced to mild or less, and 75.7% of the patients had recovered to no or trivial TR.

The one-year safety results showed:

All-cause mortality	(10.32%)
Cardiogenic mortality	(4.76%)
Incidence of renal failure	(4.0%)
Incidence of hepatic failure	(2.4%)
Incidence of grade III atrioventricular block or need for permanent pacemaker implantation	(1.6%)
Intraoperative conversion to surgical valve replacement or valvuloplasty	(0.8%)
Stroke	(2.4%)
Incidence of pulmonary infarction	(0)
Valve stent fracture	(0)

At 30 days of follow-up, 66.3% of patients' NYHA cardiac functions improved from preoperative grade III/IV to grade I/II; at one year of follow-up, 79.8% of patients improved from preoperative grade III/IV to grade I/II, demonstrating the product's ability to continuously improve patients' cardiac functions. 6MWD (6-minute walking distance) increased from the baseline of 324.3m to 333.6m at 30 days of follow-up, and to 383.2m at one year of follow-up, significantly improving the patients' quality of life.

As of the date of this announcement, nearly 500 implantation cases have been completed worldwide for the transcatheter tricuspid valve replacement system series independently developed by the Company, with the longest follow-up record of more than five years. We are looking forward to the official approval of LuX-Valve products of our transcatheter tricuspid valve replacement system in China in the near future, and commercialization as soon as possible, and will continue to advance the clinical trials and commercialization of the transcatheter tricuspid valve replacement system product series in China, Europe, North America and Asia Pacific region to benefit more patients with severe TR.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, November 27, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.